Response to neoadjuvant chemotherapy in children with pineoblastoma.
BACKGROUND
The outlook of children with pineoblastoma treated with radiation therapy alone is extremely poor, but neoadjuvant chemotherapy has been tried only in a few cases of this rare childhood brain tumor with poor prognosis.


METHODS
Three consecutive children 3 to 7 years of age received neoadjuvant chemotherapy consisting of etoposide 100 mg/m2 days 1 to 3, cisplatin 100 mg/m2 day 1, and vincristine 1.5 mg/m2 day 1, repeated every 4 weeks. After four courses of chemotherapy, patients underwent craniospinal irradiation. The radiation doses to the primary site ranged from 5040 to 5440 cGy and craniospinal axis radiation dose was 2520 to 3060 cGy.


RESULTS
After chemotherapy, mild myelosuppression occurred in all three and mild to moderate bilateral high-frequency sensorineural hearing loss occurred in two of the three patients. One patient remains in near complete resolution of the tumor at 2 years after diagnosis and another remains in CR for 5 years. One patient achieved PR for 5 months but eventually died of progressive tumor.


CONCLUSIONS
This study suggests that the neoadjuvant chemotherapy as used here is effective and has acceptable toxicity.
Ghim
T T
TT
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322.
Davis
P
P
Seo
J J
JJ
Crocker
I
I
O'Brien
M
M
Krawiecki
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D016371:Cranial Irradiation; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D010871:Pinealoma / Q000188:drug therapy* / Q000532:radiotherapy*; D012074:Remission Induction; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D005047:Etoposide; D002945:Cisplatin